TORONTO and GLIL YAM, Israel — IM Cannabis Corp., a medical cannabis company with operations in Israel and Germany, filed a shelf registration statement on Form F-3 with the Securities and Exchange Commission (SEC). The registration will allow the Company to offer and sell up to an aggregate of $50 million of its common shares, warrants, units, or a combination thereof on a registered basis, subject to market conditions, the Company’s capital needs, and limitations imposed by SEC rules and applicable securities laws.
The terms of any such offering, including the specific terms and prices of the Securities, will be determined at the time of such offering and be made solely by means of the prospectus included in the Registration Statement and any prospectus supplement that may be filed with the SEC relating to such offering.
The Shelf Registration does not constitute a commitment by the Company to sell any specific amount of Securities. Any further offerings under the Shelf Registration, if made, will be subject to the Company’s discretion and applicable market conditions.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) is an international cannabis company that provides cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets in Europe. The Company leverages a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain. The IMC ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
